Related Experiment Video

Updated: May 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer

Saby George1, Roberto Pili

  • 1Genitorurinary Program, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. Saby.George@RoswellPark.org

Current Oncology Reports
|January 22, 2013
PubMed

Insights

Tasquinimod shows significant clinical activity in patients with castration-resistant prostate cancer (CRPC). This novel targeted therapy has antiangiogenic and immunomodulatory properties, offering a new treatment option for CRPC.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Castration-resistant prostate cancer (CRPC) treatment has advanced with new therapies.
  • Androgen deprivation and chemotherapy are standard CRPC treatments.
  • Targeted agents are emerging for CRPC management.

Purpose of the Study:

  • To evaluate the clinical activity of tasquinimod in CRPC patients.
  • To investigate tasquinimod's potential as a novel targeted therapy.

Main Methods:

  • A Phase II clinical trial was conducted.
  • The study included asymptomatic or minimally symptomatic, chemotherapy-naïve CRPC patients.

Main Results:

  • Tasquinimod demonstrated significant clinical activity in the studied CRPC patient group.
  • Preclinical models showed tasquinimod possesses antiangiogenic and antitumor properties.

Conclusions:

  • Tasquinimod represents a novel targeted therapy for CRPC.
  • Its unique mechanism of action involves antiangiogenic and immunomodulatory effects.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...